Drug Trial Radar · NCT00035451
Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.
Last checked: Nov 19, 2026Latest source record: Oct 3, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
658
Actual
Start
Feb 2001
Primary completion
Jun 2003
Study completion Jun 2003
Sponsor
- Lead sponsor
- Forest LaboratoriesAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- May 6, 2002
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Atrial fibrillation (abnormal rhythm in the upper chamber of the heart) is a common supraventricular arrhythmia (a type of abnormal heart rhythm) for which antiarrhythmic therapy is often prescribed. The primary goals of therapy are to maintain sinus rhythm (normal heart rhythm) and to reduce the occurrence of episodes of atrial fibrillation. The double-blind, placebo-controlled phase of this study is designed to evaluate the efficacy and safety of oral azimilide compared with placebo and with sotalol, an antiarrhythmic drug, in maintaining sinus rhythm in patients who require cardioversion (electric shock to correct heart rhythm) to correct atrial fibrillation. Once this phase of the study is completed, a second phase with a different study design will be conducted. The second phase is an open-label, follow-up phase to the first study. The follow-up phase will continue to evaluate the long-term safety of a daily oral dose of azimilide in patients who complete the double-blind, placebo-controlled phase of this study.
Conditions
- Atrial Fibrillation
Interventions
Azimilide DihydrochlorideDrug
125 mg azimilide tablets, twice a day for 6 months
PlaceboDrug
tablets, twice daily for 6 months
SotalolDrug
160 mg sot twice daily for 6 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- To prolong the time to first symptomatic or asymptomatic AFIB, etc eventTime frame: 6 month
Locations
129 sites in 9 countries. Site status is shown where the registry gives one.
Clinique Generale Saint Jean Service de cardiologie
Brussels, Belgium
Hospital Universitarie Erasme
Brussels, Belgium
Cliniques Univeristaires UCL Mont-Godinne Avenue Theresse 1
Yvoir, Belgium
Service de Cardilolgie CH du Pays d'Aix
Aix-en-Provence, France
CHR Besancon Service de cardiologie
Besançon, France
Hopital Gavriel Montpied Cardiologie-Maladie cardiovascularies
Clermont-Ferrand, France
Service de Cardiologie CHRU
Grenoble, France
Cardiologie Hopital Jean Rostand
Ivry-sur-Seine, France
Service de Cardiologie A Hopital Cardiologique
Lille, France
Service de Cardiologie Hopital Saint Philibert
Lomme, France
Cardilolgie Hopital Guillaume et Rene Laennec
Nantes, France
Service de Cardiologie Hopital Lariboisiere
Paris, France
Service de Cardiologie et Maladies Vascularies CHRU Pontchaillou
Rennes, France
Cardiologie CHRU St Etienne/Hopital Nord
Saint-Etienne, France
Centre Hospitalier General Hospital De Girac
Saint-Michel-sur-Orge, France
Cardiologie/Pavillon Baudot Centre Hospitalier Universitaire Purpan
Toulouse, France
Cardiologie A CHU Rangueil
Toulouse, France
Service de cardiologie Hopitaux de Brabois/CHRU Nancy
Vandœuvre-lès-Nancy, France
Erzgebirgskrankenhaus Klinik fur Innere Medizin
Annaberg, Germany
Kerckhhoff-Klinik Abteilung Klinische Pharmakologie
Bad Nauheim, Germany
Kardiologie Herzzentrum Osnabruck
Bad Rothenfelde, Germany
Dr. Schreiber Krankenhaus Neukoelin 1 Innere Rudowerstrasse, 48
Berlin, Germany
Franz-Volhard-Klinik Abteilung fur Elektrophysiologie
Berlin, Germany
Stadisches Klinikum Brandenburg Med-Klinik I/Kardiologie Pulmologie und Angiologie
Brandenburg, Germany
Klinikum Coburg II Med. Klinik
Coburg, Germany
Klinkum Lippe-Detmold Med. Klink II-Kardiologie
Detmold, Germany
Krankenhaus Duren Medizinische Klinik I Kardiologie/Angiologie
Düren, Germany
Klinikum Erfurt GmbH
Erfurt, Germany
Medizinische Universitaetsklinik Innere Medizin III Kardiologie und Angiologie
Frieburg, Germany
Universitatsklinikum Hamburg-Eppendork Klinik und Poliklinik fur Innere Medizin Abteilung Kardiologie
Hamburg, Germany
Medizinische Hochschule Innere Medizin/Abt. fur Kardiologie
Hanover, Germany
Universitatsklinikum Heidelberg
Heidelberg, Germany
Medizinische Universitats-und Ploiklinik Innere Medizin 3
Homburg, Germany
Klinikum Kassel Medizinische Klinik II
Kassel, Germany
Universitate zu Koeln Klinik III fur Innere Medizin
Koeln (Lindenthal), Germany
Universitat Leipzig Medizinische Klinik und Poliklinik 1 Abteilung fur Kardiologie and Angiolgie
Leipzig, Germany
Klinikum der Stadt Ludwigshafen Abteilung fur Elektrophysiologie der Kardiologie/Herzzentrum
Ludwigshafen, Germany
Medizinische Klinik und Poliklnik Innere Medizin C
Mannheim, Germany
Medizinische Klinik und Poliklinik Innere Medizin C
Münster, Germany
Klinik am See REHA-Zentrum fur Herz und Kreislauf
Rüdersdorf, Germany
Showing 40 of 129 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.